Å·²©¼¯ÍÅÒµÎñ | È«Ãæ½âÎöйÚÅ·²©¼¯ÍŹÙÍøÎïÁòËáôÇÂÈàÆ¬µÄÑз¢ÓëÊг¡
·¢²¼Ê±¼ä£º
2020-05-09
À´Ô´£º
µ¼¶Á£º
ÁòËáôÇÂÈàÊÇйڷÎÑ×ÖÎÁÆÅ·²©¼¯ÍŹÙÍøÎïµÄ½¹µãÆ·ÖÖ£¬ÃÀ¹ú×ÜÍ³ÌØÀÊÆÕÔø¶à´Î¹«¿ªÍƼö£¬ÖÓÄÏɽԺʿҲÃ÷È·ÈÏ¿ÉÆäÁÆÐ§£¬ÃÀ¹úFDA¸üÔÚ3ÔÂ28ÈÕÇ©·¢Á˽ô¼±Ê¹ÓÃÊÚȨ¡£
¾ÝÏà¹ØÑо¿·ÖÎö±íÃ÷£¬2018ÄêÁòËáôÇÂÈà¹úÄÚÊг¡Ô¼10ÒÚÔª£¬ÔÚйÚÒßÇéÏÂÈÔÓнϴóÌáÉý¿Õ¼ä¡£µ«Ä¿Ç°¹úÄÚ½öÓÐÁ½¼Ò¿ÉÅú²ú£ºÔÑÐÈüŵ·ÆºÍ¹úÄÚ·ÂÖÆ³§¼ÒÉÏÅ·²©¼¯ÍŹÙÍøÖÐÎ÷ÖÆÅ·²©¼¯ÍŹÙÍø£¨ÉϺ£Ò½Å·²©¼¯ÍŹÙÍø £© ¡£¾ÝÉϺ£Ò½Å·²©¼¯ÍŹÙÍøÄ걨Åû¶£¬ÆäëÀûÂÊÔ¼70%¡£
¶ÔÅ·²©¼¯ÍŹÙÍøÆó¶øÑÔ£¬ÈôÏëÔÚйڷÎÑ×ÖÎÁÆÅ·²©¼¯ÍŹÙÍøÎïÖÐÕ¼¾Ýһϯ֮µØ£¬ÁòËáôÇÂÈàÊÇ×î¼ÑÑ¡Ôñ¡£½ñÄêÒÔÀ´£¬³ýÉϺ£Ò½Å·²©¼¯ÍŹÙÍøºÍÈüŵ·ÆÒѽøÐв¹³äÉêÇëÍ⣬Î÷°²º£ÐÀÖÆÅ·²©¼¯ÍŹÙÍø¡¢½ËÕÖªÔ¡¢½ËÕÉñ»ªµÈÒ²ÉêÇëÁË·ÂÖÆ£¬¹ãÉúÌÃÅ·²©¼¯ÍŹÙÍøÒµÒ²Ðû²¼Óë±±¾©Ñô¹âŵºÍ¹²Í¬Ñз¢ÁòËáôÇÂÈàÆ¬¡£
È»¶ø£¬ÁòËáôÇÂÈàµÄÑз¢´æÔÚÒ»¶¨ÄѶȣºÔÓÖÊÆ×¡¢ÔÓÖʺ¬Á¿²»È·¶¨£¬Îȶ¨ÐÔÉв»Ã÷È·£¬Å·²©¼¯ÍŹÙÍøÑ§ÖÊÁ¿¿ØÖÆÄѶȴ󣻲»Á¼·´Ó¦¶à£¬ºÍÐí¶àÅ·²©¼¯ÍŹÙÍøÎï´æÔÚÏ໥×÷Óã¬ÁÙ´²Ñо¿ÄѶȴóµÈ¡£
±¾ÎÄͨ¹ý¶ÔÁòËáôÇÂÈàÆ¬Êг¡Ç°¾°ºÍÑз¢ÒªµãµÄ½âÎö£¬Ï£ÍûΪ¹ã´óҽŷ²©¼¯ÍŹÙÍøÍ¬ÈÊÑз¢¹¤×÷´øÀ´²Î¿¼¡£Å·²©¼¯ÍÅÉúÎï¿ÉÌṩ“Å·²©¼¯ÍŹÙÍøÑ§+ÁÙ´²”һվʽŷ²©¼¯ÍŹÙÍøÎïÑз¢·þÎñ£¬ÖúÁ¦Å·²©¼¯ÍŹÙÍøÆóʵÏÖÍäµÀ³¬³µ£¡
Ŀ¼
1¡¢Å·²©¼¯ÍŹÙÍøÆ·¸ÅÊö
2¡¢Êг¡ÐÅÏ¢
3¡¢Å·²©¼¯ÍŹÙÍøÑ§¼°BEÑо¿Çé¿ö
4¡¢²Î¿¼×ÊÁϼ°ÎÄÏ×
1¡¢Å·²©¼¯ÍŹÙÍøÆ·¸ÅÊö
1.1 Æ·ÖÖ½éÉÜ
ÁòËáôÇÂÈàÆ¬£¬Ó¢ÎÄÃû³ÆHydroxychloroquine Sulfate Tablets£¬Æ¬¼Á£¬¹æ¸ñ0.2 g.
ôÇÂÈà( hydroxychloroquine£¬HCQ) ÊÇ¿ÆÑ§¼ÒÓÚ 1946 ÄêÔÚÂÈàµÄ»ù´¡ÉÏÑо¿³öµÄ 4-°±»ùàßøÀàµÄÐÂÐÍ¿¹Å±Å·²©¼¯ÍŹÙÍø£¬ÓÚ 1955 Äê¾¹ýÃÀ¹úʳƷŷ²©¼¯ÍŹÙÍøÆ·¼à¶½¹ÜÀí¾Ö( FDA) Åú×¼ÓÃÓÚÖÎÁÆÏµÍ³ÐÔºì°ßÀÇ´¯¡£ÓëÂÈàÏà±È£¬Æä½á¹¹¶àÒ»¸öôÇ»ù»ùÍÅ£¬ÕâʹÆäÔÚ±£ÁôÔÓÐÂÈàÅ·²©¼¯ÍŹÙÍøÐ§µÄͬʱ£¬¶¾¸±×÷ÓýÏÂÈàÏÔÖø½µµÍ¡£
£¨1£©½á¹¹Ê½
£¨2£©CAS£º747-36-4
·Ö×Óʽ£ºC18H26ClN3O·H2SO4
·Ö×ÓÁ¿£º433.95
1.1.1 ³É·ÖÐÔ×´
±¾Æ·Ö÷Òª³É·ÝΪÁòËáôÇÂÈà¡£Æä»¯Ñ§Ãû³ÆÎª£º2-[[4-[£¨7-ÂÈ-4-àßø»ù£©°±»ù]Îì»ù]ÒÒ°±»ù]-ÒÒ´¼ÁòËáÑΡ£±¾Æ·ÐÔ״Ϊ±¡Ä¤ÒÂÆ¬£¬³ýÈ¥°üÒºóÏÔ°×É«»òÀà°×É«¡£
1.1.2 ÊÊÓ¦Ö¢
Àà·çʪ¹Ø½ÚÑ×£¬ÇàÉÙÄêÂýÐԹؽÚÑ×£¬ÅÌ×´ºì°ßÀÇ´¯ºÍϵͳÐÔºì°ßÀÇ´¯£¬ÒÔ¼°ÓÐÑô¹âÒý·¢»ò¼Ó¾çµÄƤ·ô²¡±ä¡£Ò²¿ÉÓÃÓÚÖÎÁƼ°Ô¤·À·Ç¸´ÔÓÐÔű¼²¡£
1.1.3 Ó÷¨ÓÃÁ¿
¿Ú·þ£¬³ÉÈËÿÈÕ0.4 g£¬·Ö1¡«2´Î·þÓ㬸ù¾Ý²¡È˵ķ´Ó¦£¬¸Ã¼ÁÁ¿¿É³ÖÐøÊýÖÜ»òÊýÔ¡£³¤ÆÚά³ÖÖÎÁÆ£¬¿ÉÓýÏСµÄ¼ÁÁ¿£¬Ã¿ÈÕ0.2 g¡«0.4 g¼´¿É¡£
1.1.4 ²»Á¼·´Ó¦
ѪҺºÍÁܰÍϵͳ¼²²¡£º¹ÇËèË¥½ß£¬Æ¶Ñª£¬ÔÙÉúÕϰÐÔÆ¶Ñª£¬Á£Ï¸°ûȱ·¦Ö¢£¬°×ϸ°û¼õÉÙÖ¢ºÍѪС°å¼õÉÙÖ¢¡£¾Ý±¨µÀ»¼ÓÐÆÏÌÑÌÇ-6-Á×ËáÍÑÇâø£¨G-6-PD£©È±·¦Ö¢µÄÈË·¢ÉúÈÜѪ£»
ÐÄÔ༲²¡£ºÐ¡£¬¿ÉÄܵ¼ÖÂÐÄÁ¦Ë¥½ß£¬ÔÚijЩÇé¿öÏÂÉõÖÁÊÇÖÂÃüµÄºó¹û¡£ÑÓ³¤QT¼ä¸ô£¬ÊÒÐÔÐÄÂÉʧ³£ºÍ¼â¶ËŤתÐÔÐ͝¹ýËÙ£»
¶ú¶äºÍÃÔ·¼²²¡£ºÑ£ÔΣ¬¶úÃù£¬ÑÛÇòÕð²ü£¬Éñ¾ÐÔ¶úÁû£¬¶úÁû£»
ÑÛ²¿¼²²¡£º²»¿ÉÄæÐÔÊÓÍøÄ¤²¡±ä£¬ÊÓÍøÄ¤É«ËØ³Áןı䣨ţÑÛÍâ¹Û£©£¬ÊÓҰȱËð£¨ÖÐÑë½üÊÓ£©ºÍÊÓ¾õÕϰ£¨ÊÓÃô¶È£©£¬»Æ°ß²¡±ä£¨»Æ°ß±äÐÔ£©£¬°µÊÊÓ¦½µµÍ£¬É«¾õÒì³££¬½ÇĤ¸Ä±ä£¨Ë®Ö׺ͻì×Ç£©£©£¬°üÀ¨ÓлòûÓаéËæÖ¢×´£¨¹âÔΣ¬Î·¹â£¬ÊÓÁ¦Ä£ºý£©µÄÅ·²©¼¯ÍŹÙÍøÎï½ÇĤ³Á»ý£»
賦µÀ¼²²¡£º¶ñÐÄ£¬Å»Í£¬¸¹ÐººÍ¸¹Í´£»
Ò»°ã¼²²¡ºÍ¸øÅ·²©¼¯ÍŹÙÍø²¿Î»Çé¿ö£ºÆ£ÀÍ£»
¸Îµ¨¼²²¡£º¸Î¹¦Äܼì²éÒì³££¬¼±ÐÔ¸ÎË¥½ß£»
ÃâÒßϵͳ¼²²¡£ºÝ¡ÂéÕѪ¹ÜÐÔË®Ö×£¬Ö§Æø¹Ü¾·ÂΣ»
´úлºÍÓªÑøÊ§µ÷£ºÊ³ÓûϽµ£¬µÍѪÌÇ£¬ß²ßøÖ¢£¬ÌåÖØ¼õÉÙ£»
¼¡Èâ¹Ç÷ÀºÍ½áµÞ×éÖ¯¼²²¡£º¸Ð¾õÔ˶¯Òì³££¬¹Ç÷À¼¡¼¡²¡»òÉñ¾¼¡²¡£¬µ¼Ö½ü¶Ë¼¡ÈâȺ½øÐÐÐÔÎÞÁ¦ºÍήËõ£¬¼¡ëì·´Éä½µµÍºÍÉñ¾´«µ¼Òì³££»
Éñ¾ÏµÍ³¼²²¡£ºÍ·Í´£¬Í·ÔΣ¬ñ²ð¹²¼Ãʧµ÷ºÍ×¶ÌåÍâϵ¼²²¡£¬ÀýÈ缡ÕÅÁ¦Õϰ£¬Ô˶¯ÕϰºÍÕð²ü£»
¾«Éñ¼²²¡£ºÓ°Ïì/ÇéÐ÷²»ÎÈ£¬Éñ¾ÖÊ£¬Ò×Å£¬Ø¬ÃΣ¬¾«Éñ²¡£¬×ÔɱÐÐΪ¡£
1.1.5 Å·²©¼¯ÍŹÙÍøÑ§ÐÅÏ¢
1.1.5.1 Å·²©¼¯ÍŹÙÍøÀí»úÖÆ
ôÇÂÈà¾ßÓп¹Å±¡¢ÃâÒßµ÷½Ú¡¢¿¹²¡¶¾¡¢¿¹¾úºÍ¿¹Õæ¾úµÈÅ·²©¼¯ÍŹÙÍøÀíѧ×÷Óá£×÷ÓûúÖÆÓëÛÏ»ùµÄÏ໥×÷ÓᢸÉÈÅøµÄ»îÐÔ¡¢ºÍDNA½áºÏ¡¢Îȶ¨ÈÜøÌåĤ¡¢ÒÖÖÆÇ°ÁÐÏÙËØµÄÐγɡ¢ÒÖÖÆ¶àÐκËϸ°ûµÄÇ÷»¯×÷ÓúÍÍÌÊÉϸ°ûµÄ×÷ÓᢿÉÄܸÉÈŵ¥ºËϸ°û°×½éËØ1µÄÐγɺÍÒÖÖÆÖÐÐÔÁ£Ï¸°û³¬Ñõ»¯ÎïµÄÊÍ·Å¡£ôÇÂÈàµÄ¿¹Å±×÷ÓûúÖÆÓëÂÈàÏàËÆ£¬Í¨¹ý×èÖ¹ÑÇÌúѪºìËØ¾ÛºÏΪűԳæÉ«ËØ£¬¶ø·¢»Ó¿¹Å±×÷Óá£ôÇÂÈà¿ÉÒÔÒÖÖÆT ϸ°ûµÄÔöÖ³£¬¼õÉÙ´ÙÑ×ÐÔϸ°ûÒò×ӵIJúÉú£¬ÀýÈçINF-γ¡¢TNF¡¢IL-1¡¢IL-6 ºÍIL-2£¬»¹Äܹ»×èÖ¹Toll ÑùÊÜÌå( toll-like receptors£¬TLR) ÓëºËËáÅäÌåµÄÏ໥×÷Ó㬴Ӷø¼õÉÙÏÈÌìÐÔÃâÒߵļ¤»î¡£
ôÇÂÈàµÄ¿¹²¡¶¾×÷ÓûúÖÆÉÐδÍêÈ«Çå³þ¡£ÓÐÑо¿ÕßÈÏΪ£¬ôÇÂÈàÊÇÇ×Ö¬µÄÈõ¼î£¬½ÏÈÝÒ×ͨ¹ýϸ°ûÖÊĤÔÚÈÜøÌå¾Û¼¯£¬ÈÜøÌåÖиßŨ¶ÈµÄôÇÂÈàÄܽ«ÈÜøÌåµÄpH Öµ´ÓÕý³£Öµ( 4.7-4.8) Ôö¼ÓÖÁ6.0£¬´Ó¶øÓ°ÏìÈÜøÌåÖе°°×øµÄ»îÐÔ£¬¸ÉÈÅÈÜøÌåµÄÕý³£¹¦ÄÜ£¬½ø¶ø·¢»Ó¿¹²¡¶¾×÷Óá£ÁíÍ⣬ÓÐÑо¿±íÃ÷ôÇÂÈà¿Éͨ¹ý¸Ä±äѪ¹Ü½ôÕÅËØ×ª»¯Ã¸2( ACE2) ÊÜÌåµ°°×µÄÌÇ»ù»¯ÐÞÊΣ¬×è¶Ï²¡¶¾½øÈëÈËÌåϸ°û£¬´Ó¶øÒÖÖÆ²¡¶¾µÄÇÖÈë¡£
1.1.5.2 BCS·ÖÀà
¢óÀà¡£
1.1.5.3 Å·²©¼¯ÍŹÙÍø´ú¶¯Á¦Ñ§²ÎÊý

1.1.5.4 תÔËÌå¼°´úлøµÈ
תÔËÌ壺ABCB1£¨ÒÖÖÆ£©£»SLCO1A2£¨ÒÖÖÆ£©
´úлø: CYP3A4£¨µ×Î£»CYP2D6£¨ÒÖÖÆ£©
LogP£º/£»pKa£º9.67£»
1.2 Ñз¢Çé¿ö
¹úÄÚ½öÓÐÁ½¼ÒÅú²ú£ºÔÑÐAventis Pharma LimitedºÍ¹úÄÚ·ÂÖÆ³§¼ÒÉϺ£ÉÏÅ·²©¼¯ÍŹÙÍøÖÐÎ÷ÖÆÅ·²©¼¯ÍŹÙÍøÓÐÏÞ¹«Ë¾¡£±¾Æ·ÊôÓÚ×¢²á·ÖÀà4À࣬Ŀǰ±¾Æ·ÔÚ¹úÄÚÒÑÓÐ1¼ÒÅ·²©¼¯ÍŹÙÍøÆóÉÏÊУ¬1¼ÒÅ·²©¼¯ÍŹÙÍøÆóÒÑÌá½»É걨×ÊÁÏ£¬2¼ÒÅ·²©¼¯ÍŹÙÍøÆóÍê³ÉÁÙ´²ÊÔÑ飬1¼ÒÅ·²©¼¯ÍŹÙÍøÆóÕýÔÚÉ걨һÖÂÐÔÆÀ¼Û£¨¾ßÌåÏê¼ûÅ·²©¼¯ÍŹÙÍøÑ§¼°BEÑо¿Çé¿ö£©¡£
2 Êг¡ÐÅÏ¢
2.1 ÏúÊÛÇé¿ö
2.1.1 ÏúÊÛ¼Û¸ñ
Áгö¼¸ÖÖ³£¼û²úÆ·µÄÏúÊÛ¼Û¸ñ£¬Ïê¼ûÏÂ±í¡£
×¢£º±í¸ñÐÅÏ¢²Î¿¼Å·²©¼¯ÍŹÙÍøÖÇÍø¡£
2.1.2 Êг¡ÏúÊÛ¶î
ÁòËáôÇÂÈà¹úÄÚ½öÉÏÅ·²©¼¯ÍŹÙÍøÖÐÎ÷ÖÆÅ·²©¼¯ÍŹÙÍø£¨ÉϺ£Ò½Å·²©¼¯ÍŹÙÍø£©³ÖÓÐÉú²úÅúÎÄ£¬ÁíÓÐÈüŵ·ÆÁòËáôÇÂÈà½ø¿Ú¡£ÓÉÓÚÖ÷ÒªÊÊӦ֢Ϊ×ÔÉíÃâÒßÀ༲²¡£¬¸Ã²úÆ·ÏúÊÛ¶îÔ¶¸ßÓÚÁ×ËáÂÈà¡£ÖÁ2016Ä꣬ÒÑÊÇÃÀ¹ú´¦·½´ÎÊý×î¶àµÄ135ÖÖÅ·²©¼¯ÍŹÙÍøÎïÖ®Ò»¡£2018ÄêÎÒ¹úÁòËáôÇÂÈàÏúÊÛ¶î´ï10.92ÒÚÔª£¬ÆäÖÐÉÏÅ·²©¼¯ÍŹÙÍøÖÐÎ÷ÖÆÅ·²©¼¯ÍŹÙÍøÊг¡·Ý¶î´ï75.54%£¬Èüŵ·ÆÊг¡·Ý¶îΪ24.46%¡£½ü¼¸ÄêÁòËáôÇÂÈàÆ¬È«¹úÏúÊ۶ͬ±ÈÔöËÙÐÅÏ¢ÈçÏ£º

×¢£ºÊý¾ÝÀ´Ô´Öйú²úÒµÐÅÏ¢Íø
ÈÕǰ£¬ÔÚÈ«ÇòµÚÒ»ÍÆÏúÔ±ÌØÀÊÆÕÏÈÉúµÄÖú¹¥Ï£¬È«Çò·èÇÀÂÈàºÍôÇÂÈà¡£¾ÝÁ˽⣬¸ÃÅ·²©¼¯ÍŹÙÍøÎïµÄÔÁÏÅ·²©¼¯ÍŹÙÍø´Ó֮ǰµÄ1000ÔªÒÔÄÚ·èÕǵ½7000-8000Ԫÿ¹«½ï£¬²¢ÇÒ»¹ÐèÒªÅÅÆÚµÈ»õ£¬ ²»ÉÙ¹«Ë¾Ò²Òò´Ë׬µÃÅèÂú²§Âú¡£´Ó3ÔÂ19ÈÕÌØÀÊÆÕ¼ÇÕß»áÉÏÍÆÏúÂÈàÆð£¬ÂÈà¸ÅÄîµÄÉϺ£Ò½Å·²©¼¯ÍŹÙÍø£¨601607£©Ò²ÀÛ»ýÉÏÕÇÁË15%¡£
2.2 Êг¡·ÖÎö
2.2.1 Êг¡¸Å¿ö
ÁòËáôÇÂÈà1955ÄêÔÚÃÀ¹úÉÏÊУ¬ÓÃÓÚű¼²¡¢Àà·çʪÐԹؽÚÑס¢ºì°ßÀÇ´¯ÖÎÁÆ¡£¸ÃÆ·ÖÖÒÑÔÚ¼ÓÄô󡢷¨¹ú¡¢µÂ¹ú¡¢°Ä´óÀûÑÇ¡¢Öйú¡¢ÈÕ±¾µÈ70¶à¸ö¹ú¼Ò»ñµÃÅú×¼¡£ÔÚÃÀ¹úºÍÅ·ÖÞÓжà¼Ò·ÂÖÆÅ·²©¼¯ÍŹÙÍøÉÏÊУ¬µ«ÔÚ¹úÄÚ½öÓÐÁ½¼ÒÅú²ú£ºÔÑÐAventis Pharma LimitedºÍ¹úÄÚ·ÂÖÆ³§¼ÒÉϺ£ÉÏÅ·²©¼¯ÍŹÙÍøÖÐÎ÷ÖÆÅ·²©¼¯ÍŹÙÍøÓÐÏÞ¹«Ë¾¡£ÁòËáôÇÂÈàÆ¬Êг¡¸ñ¾ÖÈçÏ£º

×¢£ºÊý¾ÝÀ´Ô´Öйú²úÒµÐÅÏ¢Íø
´ËÅ·²©¼¯ÍŹÙÍøÆ·µÄ¹úÄÚÊг¡±»ÉϺ£Ò½Å·²©¼¯ÍŹÙÍø¼¯ÍźÍÈüŵ·ÆÖÆÅ·²©¼¯ÍŹÙÍø¹«Ë¾Â¢¶Ï¡£µ«²»·¦¾ºÕùÕߣ¬±ÈÈçÔÚ2020Äê4Ô£¬¹ãÉúÌúͱ±¾©Ñô¹âŵºÍ´ï³ÉºÏ×÷£¬¹²Í¬¿ª·¢ÁòËáôÇÂÈàÆ¬£¬Ì½¾¿ÆäÔÚйڷÎÑ×ÖÎÁÆÖеÄ×÷Óá£
2.2.2 Êг¡Ç°¾°·ÖÎöºÍѧÊõ±¨µÀ
ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×( coronavirus disease-19£¬COVID-19) µÄ¸ÐȾÈËÊý²»¶ÏÔö¼Ó£¬Ò½ÁÆÐÎÊÆÊ®·ÖÑϾþ£¬Ç±ÔÚÖÎÁÆÅ·²©¼¯ÍŹÙÍøÎï¡¢ÒßÃçÓë¸Éϸ°ûÌæ»»·½·¨²»¶ÏÓ¿ÏÖ£¬Ñ°ÕÒÌØÐ§µÄÖÎÁÆÅ·²©¼¯ÍŹÙÍøÎïºÍ×î¼ÑµÄÖÎÁÆ·½°¸ÆÈÔÚü½Þ¡£
ÔçÔÚ½ñÄê¶þÔÂÎ人´óѧÈËÃñÒ½ÔºÔø·¢²¼ÏûÏ¢³Æ£¬·¢ÏÖôÇÂÈà¶ÔйڷÎÑ×»¼ÕßÖÎÁÆÓÐЧ¹û¡£¸ÃÔºÔÚÁÙ´²ÊÔÑéÖУ¬20Àý»¼ÕßÔÚʹÓÃôÇÂÈàÅ·²©¼¯ÍŹÙÍøÎïºó£¬Ö¢×´³öÏÖºÃת¡£ÉϺ£ÊпªÕ¹ôÇÂÈàÖÎÁÆÇáÖжÈйڲ¡¶¾·ÎÑ×µÄÈ«¹ú¶àÖÐÐÄÁÙ´²Ñо¿£¬ÒÑÈë×é184Àý¡£³õ²½½á¹ûÏÔʾôÇÂÈàÖÎÁÆÓÐЧÇÒ¸ü°²È«£¬ÔÚ“ÉϺ£·½°¸”ÖÐÖÎÁÆÐÔÅ·²©¼¯ÍŹÙÍøÎïÁÐÊ×λ¡£ÂÈàÔÚСÑù±¾ÁÙ´²ÊÔÑéÖÐÕ¹ÏÖÁËÓÅÓÚÂ寥ÄÇΤ /ÀûÍÐÄÇΤ( ¿ËÁ¦Ö¥) µÄÁÙ´²¿¹²¡¶¾ÖÎÁÆÐ§¹û¡£¼øÓÚÂÈàÔÚÈÕǰµÄСÑù±¾ÁÙ´²ÊÔÑéÖÐÒѾ³õ²½Õ¹ÏÖÁËÓÅÓÚÂ寥ÄÇΤ/ÀûÍÐÄÇΤ( ¿ËÁ¦Ö¥) µÄÖÎÁÆÐÂÐ͹Ú×´²¡¶¾·ÎÑ×( COVID-19 ) µÄÁÙ´²Ð§¹û£¬Òѱ»ÄÉÈëÁ˹ú¼ÒÎÀÉú½¡¿µÎ¯Ô±»á¡¶ÐÂÐ͹Ú×´²¡¶¾·ÎÑ×ÕïÁÆ·½°¸( ÊÔÐеÚÁù°æ) ¡·£¬½üÈչ㶫ʡ¿Æ¼¼Ìü¼°¹ã¶«Ê¡ÎÀÉú½¡¿µÎ¯Á×ËáÂÈàÖÎÁÆÐ¹Ú×´²¡¶¾·ÎÑ×¶àÖÐÐÄÐ×÷×éÓÖ³ǫ̈ÁË¡¶Á×ËáÂÈàÖÎÁÆÐÂÐ͹Ú×´²¡¶¾·ÎÑ×µÄר¼Ò¹²Ê¶¡·£¬ÕâЩ²Î¿¼Ö¸ÄÏΪ¿¹Ð¹ڲ¡¶¾Ö¸Ã÷ÁË·½Ïò²¢Ìá³öÁËеÄÌôÕ½¡£
·¨¹úĿǰҲÓÐÒ»Ïî36ÀýµÄÁÙ´²ÊÔÑé½á¹ûÏÔʾ£¬½ÓÊÜôÇÂÈàºÍ°¢ÆæÃ¹ËØÁªºÏÖÎÁƵϼÕߣ¬µÚ6Ìì±ÇÑÊÊÃ×Ó²¡¶¾×ªÒõÂÊΪ100£¥£»ôÇÂÈ൥ŷ²©¼¯ÍŹÙÍøÖÎÁƵϼÕßΪ57.1£¥£»¶ÔÕÕ×éΪ12.5£¥£¨p<0.001£©£¬²¢ÇÒÓëÎÞÖ¢×´»¼ÕßÏà±È£¬¾ßÓÐÖ¢×´µÄ»¼ÕßÅ·²©¼¯ÍŹÙÍøÎïÁÆÐ§¸üÏÔÖø¡£2020Äê3ÔÂ28ÈÕ£¬ÃÀ¹úFDA½ô¼±Åú×¼ÁòËáôÇÂÈàºÍÁ×ËáÂÈàÓÃÓÚÖÎÁÆCOVID-19µÄÁÙ´²ÊÔÑé¡£2020Äê4ÔÂ21ÈÕ£¬Ò»ÏîÓÉÃÀ¹ú¹úÁ¢ÎÀÉúÑо¿ÔººÍ¸¥¼ªÀûÑÇ´óѧ£¨National Institutes of Health and the University of Virginia.£©×ÊÖúµÄÑо¿±íÃ÷£º“½ÓÊÜôÇÂÈàÖÎÁƔйڷÎÑ׵ĶÔÕÕ×飬“ËÀÍöÂʸü¸ß”£¡ÕâÏîÔÚÃÀ¹úÍËÎé¾üÈËÎÀÉú¹ÜÀí¾ÖÒ½ÁÆÖÐÐĽøÐеÄÑо¿ÖУ¬ ¶Ô368λ»¼Õß½øÐÐÁ˱ȶԣ¬ÓÐ97λ·þÓÃôÇÂÈàµÄ»¼ÕßËÀÍöÂÊΪ27.8£¥¡£158Ãûδ·þÓøÃÅ·²©¼¯ÍŹÙÍøµÄ»¼ÕßËÀÍöÂÊΪ11.4£¥¡£µ«ÊÇ£¬¸ÃҽѧÎÄÕ´ýÆÀÉó£¬ÔÝδ·¢±í¡£
ôÇÂÈàÊÇ·ñ¾ßÓжÔйڷÎÑ×µÄÖÎÁÆ×÷Ó㬻¹ÐèÒª¸ü¶àÑо¿½á¹ûµÄ·¢±í֤ʵ¡£ÔÚµ±½ñÐÎÊÆÏ£¬Èç¹ûÁòËáôÇÂÈàÆ¬¶ÔCOVID-19ÓÐÓÐЧÖÎÁÆ×÷Ó㬿ÉÒÔÔ¤²âôÇÂÈàÆ¬µÄÊг¡¹æÄ£ºÍÉú²úÏû·Ñ»á½øÒ»²½À©´ó£»Èç¹ûÎÞÓÐЧ×÷Ó㬽áºÏ½ü¼¸ÄêÏúÊÛ¶îÔöËÙÐÅÏ¢£¬ÆäÊг¡¹æÄ£½«Ç÷ÓÚÆ½ÎÈÔö³¤Ì¬ÊÆ¡£
3¡¢Å·²©¼¯ÍŹÙÍøÑ§¼°BEÑо¿Çé¿ö
3.1 ±¸°¸¼°ÉóÆÀÇé¿ö
ĿǰÏúÊÛÆóÒµ£ºÔÑÐAventisPharmaLimited¡¢ÉϺ£ÉÏÅ·²©¼¯ÍŹÙÍøÖÐÎ÷ÖÆÅ·²©¼¯ÍŹÙÍøÓÐÏÞ¹«Ë¾¡£
ÔÁÏÅú²ú³§¼Ò£º6¼Ò£¬·Ö±ðΪÉϺ£ÖÐÎ÷Èýάŷ²©¼¯ÍŹÙÍøÒµÓÐÏÞ¹«Ë¾¡¢ËÕÖݳ¤Õ÷-ÐÀ¿ÖÆÅ·²©¼¯ÍŹÙÍøÓÐÏÞ¹«Ë¾¡¢¸£°²Å·²©¼¯ÍŹÙÍøÒµ¼¯ÍÅÖØÇì²©Ê¥ÖÆÅ·²©¼¯ÍŹÙÍøÓÐÏÞ¹«Ë¾¡¢Î人ÎäÅ·²©¼¯ÍŹÙÍøÖÆÅ·²©¼¯ÍŹÙÍøÓÐÏÞ¹«Ë¾¡¢ÖØÇ쿵ÀÖÖÆÅ·²©¼¯ÍŹÙÍøÓÐÏÞ¹«Ë¾¡¢½ËÕÉñ»ªÅ·²©¼¯ÍŹÙÍøÒµÓÐÏÞ¹«Ë¾¡£
CDE±¸°¸¼°×ÊÁÏÉóÆÀÇé¿ö£º

3.2 Ñо¿ÖÜÆÚ
ÁòËáôÇÂÈàÆ¬ÕûÌåÑо¿ÖÜÆÚÔ¼19¸öÔ£¬ÆäÖÐÅ·²©¼¯ÍŹÙÍøÑ§Ñо¿ÖÜÆÚÔ¼19¸öÔ£¬BEÑо¿ÖÜÆÚÔ¼7¸öÔµÄʱ¼ä¡£ÒòBEÔ¤ÊÔÑé¿ÉÒÔÔÚÅ·²©¼¯ÍŹÙÍøÑ§µÄÖÐÊÔÅú´Î·Å´ó½×¶Î£¨T+9£©ºó¿ªÕ¹£¬¹ÊÕûÌåÑо¿ÖÜÆÚÔ¼19¸öÔ¡£
3.3 Å·²©¼¯ÍŹÙÍøÑ§ºÍBEÑо¿
3.3.1 Å·²©¼¯ÍŹÙÍøÎïµÄÏ໥×÷ÓÃ
Ñо¿±íÃ÷£¬ôÇÂÈàÓëÐí¶àÀàÐ͵ÄÅ·²©¼¯ÍŹÙÍøÎï´æÔÚÒ»¶¨µÄÏ໥×÷Óã¬ÁÙ´²Ê¹ÓÃÊ±ÒªÌØ±ð×¢Ò⣬±ÜÃâÓëÒÔÏÂÅ·²©¼¯ÍŹÙÍøÎïºÏÓÃ:
( 1) ÁòËáôÇÂÈàÄܹ»Ôö¼ÓÌåÄڵظßÐÁµÄˮƽ¡£
( 2) ÑÓ³¤ QT ¼äÆÚµÄÅ·²©¼¯ÍŹÙÍøÎïºÍÆäËûÖÂÐÄÂÉʧ³£Å·²©¼¯ÍŹÙÍøÎï¡£´ËÍ⣬Èç¹ûôÇÂÈàÓëÆäËûÖÂÐÄÂÉʧ³£Å·²©¼¯ÍŹÙÍøÎïͬʱʹÓ㬿ÉÄÜ»áÔö¼ÓÓÕ·¢ÊÒÐÔÐÄÂÉʧ³£µÄ·çÏÕ¡£
( 3) ÒÑÖª¿É½µµÍ¾ªØÊãÐÖµµÄ¼×·úàºÍÆäËûÅ·²©¼¯ÍŹÙÍøÎï¡£
( 4) ¿¹ñ²ðïÅ·²©¼¯ÍŹÙÍø: ÓëôÇÂÈàºÏÓÿÉÄÜÓ°Ï쿹ñ²ðïÅ·²©¼¯ÍŹÙÍøµÄ»îÐÔ¡£
( 5) ¼×°±µûßÊ: ¼×°±µûßÊÓëôÇÂÈàÁªºÏʹÓû¹Î´±»Ñо¿£¬¿ÉÄÜ»áÔö¼Ó²»Á¼·´Ó¦µÄ·¢ÉúÂÊ¡£
( 6) »·æßËØ: µ±»·æßËØºÍôÇÂÈàÁªºÏʹÓÃʱ£¬Ñª½¬»·æßËØË®Æ½Éý¸ß¡£
3.3.2 Å·²©¼¯ÍŹÙÍø´ú¶¯Á¦Ñ§ÌØÕ÷
£¨1£©ÎüÊÕ¡¢·Ö²¼
¿Ú·þºó£¬ôÇÂÈà±»¿ìËٺͼ¸ºõÈ«²¿ÎüÊÕ¡£ÔÚÒ»ÏîÑо¿ÖУ¬¸øÓ轡¿µÊÜÊÔÕß400 mgµ¥¼ÁÁ¿µÄôÇÂÈàºó£¬Æäƽ¾ùѪ½¬·åŨ¶ÈÔÚ53-208 ng/ml·¶Î§£¬Æ½¾ùˮƽΪ105 ng/ml¡£Ñª½¬´ï·åŨ¶ÈµÄƽ¾ùʱ¼äΪ1.83Сʱ¡£Ä¸Ì廯ºÏÎïºÍ´úлÎï¹ã·º·Ö²¼ÓÚ»úÌå¡£
£¨2£©´úл¡¢ÅÅй
ôÇÂÈà¾ßÓкÍÂÈàÏàËÆµÄÅ·²©¼¯ÍŹÙÍøÀí×÷Óá¢Å·²©¼¯ÍŹÙÍø´ú¶¯Á¦Ñ§ºÍÌåÄÚ´úл¹ý³Ì¡£¸ù¾Ý¸øÅ·²©¼¯ÍŹÙÍøºóµÄʱ¼ä£¬Æ½¾ùѪ½¬Ïû³ý°ëË¥ÆÚ±ä»¯ÈçÏ£ºÑª½¬´ï·åŨ¶Èºó0-10¡¢10-48¡¢48-504Сʱ·Ö±ðΪ5.9¸öСʱ¡¢26.1¸öСʱºÍ299¸öСʱ¡£
3.3.3 ÁÙ´²Å·²©¼¯ÍŹÙÍø´ú¶¯Á¦Ñ§
Èüŵ·ÆÖÆÅ·²©¼¯ÍŹÙÍø³öÆ·µÄÁòËáôÇÂÈàÆ¬µÄÉÌÆ·Ãû³ÆÎªÈüÄÜ/ PLAQUENIL.
Ò» Á£ PLAQUENIL Ƭ ¼Áº¬ ÓÐ 200 ºÁ ¿Ë ôÇ ÂÈ à Áò Ëá ÑÎ £¬ Ïà µ± ÓÚ 155 ºÁ ¿Ë ôÇ ÂÈà¡£
¶Ô½¡¿µÄÐÐÔµ¥´Î¿Ú·þ200 mg PLAQUENILºó£¬ôÇÂÈàÆ½¾ù·åֵѪŷ²©¼¯ÍŹÙÍøÅ¨¶ÈΪ129.6 ng/mL£¬´ï·åʱ¼äΪ3.26 h£¬°ëË¥ÆÚΪ537Сʱ£¨22.4Ì죩¡£ÔÚͬÏîÑо¿ÖУ¬Ñª½¬·åֵŨ¶ÈΪ50.3 ng/mL£¬´ï·åʱ¼äΪ3.74 h£¬°ëË¥ÆÚΪ2963Сʱ£¨123.5Ì죩¡£3¸öÔºóÈԿɼì³öÄòÖÐôÇÂÈàˮƽ£¬Ô¼ÓÐ10£¥µÄ¼ÁÁ¿×÷ΪĸÌåÅ·²©¼¯ÍŹÙÍøÎïÅÅй¡£Ò»Ïîµ¥´Î·þÓÃ200 mgƬ¼ÁVS¾²ÂöÊä×¢£¨155ºÁ¿Ë£©µÄÑо¿½á¹û±íÃ÷£¬±¾Æ·°ëË¥ÆÚÔ¼ Ϊ40Ì죬·Ö²¼ÈÝ»ý´ó¡£
ÔÚôÇÂÈàµÄ´ï·åʱ¼äµÄͬʱ¹Û²ìµ½´úлÎïµÄ·åֵѪŷ²©¼¯ÍŹÙÍøÅ¨¶È¡£ÎüÊÕ¼ÁÁ¿µÄƽ¾ù·ÖÊýΪ0.74¡£·Ö±ð¾²Âö×¢Éä155 mgºÍ310 mg¼ÁÁ¿ºó£¬ÔÚ155 mgÊä×¢ºóºÍ310 mgÊä×¢ºó6¸öÔ£¬ÑªÅ·²©¼¯ÍŹÙÍøÅ¨¶È·åÖµ·¶Î§Îª1161ng/mLÖÁ2436 ng/mL£¨Æ½¾ù1918 ng/mL£©¡£Å·²©¼¯ÍŹÙÍø´ú¶¯Á¦Ñ§²ÎÊýÔÚ155 mgºÍ310 mgµÄÖÎÁƼÁÁ¿·¶Î§ÏÔʾÏßÐÔ¶¯Á¦Ñ§¡£
ÔÚ³¤ÆÚ¿Ú·þôÇÂÈàºó£¬Ñª½¬ºÍѪҺÖз¢ÏÖÁËÈýÖÖº¬Á¿¸ßµÄ´úл²úÎȥÒÒ»ùôÇÂÈࣨDHCQ£©£¬È¥ÒÒ»ùÂÈࣨDCQ£©ºÍ¶þÒÒ»ùôÇÂÈࣨBDCQ£©£¬ÆäÖÐDHCQÊÇÖ÷ÒªµÄ´úл²úÎï¡£´úл²úÎïµÄÎüÊÕ°ëË¥ÆÚԼΪ3ÖÁ4Сʱ£¬×îÖÕ°ëË¥ÆÚΪ40ÖÁ50Ìì¡£³¤µÄ°ëË¥ÆÚ¿ÉÒÔ¹éÒòÓڹ㷺µÄ×éÖ¯ÉãÈ¡£¬¶ø²»ÊÇÓÉÓÚÅÅй¼õÉÙ¡£ÔÚÔ¼3ÖÁ4СʱÄڹ۲쵽ôÇÂÈàµÄѪ½¬·åֵˮƽ¡£·þÓÃPLAQUENILÖÁÉÙÁù¸öÔµĵÄÀà·çʪ¹Ø½ÚÑ×£¨RA£©»¼ÕßµÄÉöÔàÇå³ýÂÊËÆºõÓëÖ¾Ô¸Õߵĵ¥¼ÁÁ¿Ñо¿ÏàËÆ£¬Õâ±íÃ÷³¤ÆÚ¸øÅ·²©¼¯ÍŹÙÍø²»»á·¢Éú±ä»¯¡£ÔÐÍÅ·²©¼¯ÍŹÙÍøÎïµÄÉöÔàÇå³ýÂÊ·¶Î§Ô¼Îª16£¥ÖÁ30£¥£¬Ó뼡ôûÇå³ýÂÊÎ޹ء£Òò´Ë£¬Éö¹¦Äܲ»È«»¼ÕßÎÞÐèµ÷Õû¼ÁÁ¿¡£ÔÚRA»¼ÕßÖУ¬ËùÎüÊÕ¼ÁÁ¿µÄ±ÈÀý£¨¼´30£¥ÖÁ100£¥£©²îÒìºÜ´ó£¬¼²²¡»î¶¯½ÏÉٵϼÕßÖÐôÇÂÈàˮƽÏÔÖøÉý¸ß¡£Ã¿Ìì·þÓÃôÇÂÈàµÄ»¼ÕßµÄϸ°ûˮƽÒѱ»Ö¤Ã÷»áÃ÷ÏÔÉý¸ß¡£µ¥ºËϸ°û¶àÓÚ¶àÐκ˰×ϸ°û¡£
3.4 BE·½°¸Éè¼Æ¸ÅÒª
¸ù¾ÝFDAÖ¸µ¼ÔÔò£¬±¾ÊÔÑé²ÉÓõ¥ÖÐÐÄ¡¢Ëæ»ú¡¢¿ª·Å¡¢µ¥¼ÁÁ¿¡¢Á½ÖƼÁ¡¢Æ½ÐÐÉè¼Æ£¬·ÖΪ¿Õ¸¹¸øÅ·²©¼¯ÍŹÙÍøºÍ²Íºó¸øÅ·²©¼¯ÍŹÙÍøÈËÌåÉúÎïµÈЧÐÔÑо¿Á½²¿·Ö¡£
ËùÓÐÈë×éÊÜÊÔÕßËæ»ú·ÖΪ¢ñ×éºÍ¢ò×飬ÿ×éÈËÊýÏàµÈ¡£¢ñ×éÊÜÊÔÕß·þÓÃÊÜÊÔÖÆ¼Á£¨T£©£¬¢ò×é·þÓòαÈÖÆ¼Á£¨R£©£¬¸øÅ·²©¼¯ÍŹÙÍø¼ÁÁ¿0.2 g£¬ÉúÎïÑùÆ··ÖÎö²ÉÓÃLC-MS/MS·¨²â¶¨È«ÑªÖÐôÇÂÈàµÄŨ¶È¡£

3.4.1 ÀýÊý
CDE±¸°¸ÀýÊý£¨½ØÖ¹ÖÁ2020Äê04ÔÂ17ÈÕ£©£º
1) ½ËÕÖªÔÅ·²©¼¯ÍŹÙÍøÒµÓÐÏÞ¹«Ë¾£¬2*2£¬¿Õ¸¹+²Íºó£¬48Àý£¬-72 h£¬2019-11-21ÒÑÍê³É£¬ÔÝδÌá½»×ÊÁÏ
2) Î÷°²º£ÐÀÖÆÅ·²©¼¯ÍŹÙÍøÓÐÏÞ¹«Ë¾ÒÀ¾Ý£¬Æ½ÐÐÉè¼Æ£¬¿Õ¸¹+²Íºó£¬164Àý£¬-72 h£¬2019-08-20ÒÑÍê³É£¬ÒÑÌá½»É걨×ÊÁÏ£¨2020-03-20³Ð°ì£©
3) ÉϺ£ÉÏÅ·²©¼¯ÍŹÙÍøÖÐÎ÷ÖÆÅ·²©¼¯ÍŹÙÍøÓÐÏÞ¹«Ë¾£¬Æ½ÐÐÉè¼Æ£¬¿Õ¸¹+²Íºó£¬210Àý£¬-72 h£¬2019-02-22ÒÑÍê³É£¬ÒÑÅú×¼ÉÏÊУ¨Á½¸ö¹æ¸ñ0.2ºÍ0.1g£©
3.4.2 ²ÉѪµãÉè¼Æ
¹úÄÚÍâÎÄÏ×£º
1£©0¡¢0.5¡¢1¡¢1.5¡¢2¡¢2.5¡¢3¡¢3.5¡¢4¡¢5¡¢6¡¢8¡¢10¡¢12¡¢24 h[3]
2£©0¡¢0.75¡¢1.5¡¢2¡¢2.5¡¢2.75¡¢3¡¢3.25¡¢3.5¡¢4¡¢4.5¡¢5¡¢6¡¢8¡¢13¡¢24¡¢32 h¡¢2¡¢3¡¢4¡¢5¡¢7¡¢14¡¢21¡¢28¡¢35¡¢42¡¢49¡¢56¡¢63¡¢70¡¢77 day[4]
¿Õ¸¹Ô¤ÊÔÑ飨ƽÐÐÉè¼Æ£©£º0¡¢0.5¡¢1¡¢1.5¡¢2¡¢2.5¡¢3¡¢3.5¡¢4¡¢6¡¢8¡¢10¡¢12¡¢24¡¢48¡¢72 h[2]
3.5 Å·²©¼¯ÍŹÙÍøÑ§ºÍBEÑо¿Äѵã
£¨1£©´¦·½·ÖÎöºÍ¹¤ÒÕÓÅ»¯ÒªÇó¸ß£¬Òª¾¡¿ÉÄܲÉÓÃÓëÔÑÐÅ·²©¼¯ÍŹÙÍøÏàͬµÄ¸¨Áϼ°¹¤ÒÕ¡£
£¨2£©ÔÓÖÊÆ×¡¢ÔÓÖʺ¬Á¿²»È·¶¨£¬Å·²©¼¯ÍŹÙÍøÑ§ÖÊÁ¿¿ØÖÆÄѶȴó¡£
£¨3£©Î´Óпɲο¼µÄÈܳöÇúÏßÐÅÏ¢£¬Å·²©¼¯ÍŹÙÍøÑ§Îȶ¨ÐÔ´ýÆÀ¹À¡£
£¨4£©·ÖÎö»ùÖÊΪȫѪ£¬½ÏѪ½¬ÏîÄ¿ÄѶÈÔö¼Ó¡£
£¨5£©±¾Æ·²»Á¼·´Ó¦¶à£¬ÇÒ´æÔÚºÍÐí¶àÅ·²©¼¯ÍŹÙÍøÎïµÄÏ໥×÷Óã¬ÕÐļÊÜÊÔÕßÄѶȴó¡£
£¨6£©ÕýʽÊÔÑéÀýÊý¶à£¬²Ù×÷³É±¾´ó£¬ÖÊÁ¿¹Ü¿Ø½ÏÄÑ¡£
4¡¢²Î¿¼ÎÄÏ×¼°×ÊÁÏ
[1] ÔÑÐ˵Ã÷Êé.
[2] ¿Õ¸¹Ô¤ÊÔÑéÊý¾Ý.
[3] A parallel design study to assess the bioequivalence of generic and branded hydroxychloroquine sulfate tablets in healthy volunteers[J]. Drug Research, 2012.
[4] K.K. Midha, J.W. Hubbard, M.J. Rawson, et al. The roles of stereochemistry and partial areas in a parallel design study to assess the bioequivalence of two formulations of hydroxychloroquine: A drug with a very long half life[J]. European Journal of Pharmaceutical Sciences, 1996, 4(5):0-292.
[5] Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC–MS/MS[J]. Rheumatol Ther (2015) 2:183–195.
[6] ÈÕ±¾IFÎļþºÍ˵Ã÷Êé.
[7] ¹ú¼ÒÅ·²©¼¯ÍŹÙÍøÆ·±ê×¼ÎïÖÊʹÓÃ˵Ã÷Êé.
[8] ÁòËáôÇÂÈàµÄÁÙ´²Å·²©¼¯ÍŹÙÍøÀíѧÑо¿½øÕ¹.ÖйúÁÙ´²Å·²©¼¯ÍŹÙÍøÀíѧÓëÖÎÁÆÑ§,2020.
[9] Å·²©¼¯ÍŹÙÍøÖÇÍø¡¢ÐÂÀËҽŷ²©¼¯ÍŹÙÍøÍø¡¢²úÒµÐÅÏ¢Íø¡¢ÖªÍø¡¢Íò·½¡¢¹È¸èѧÊõ¡¢PubmedµÈ.
±¾ÎÄ×÷ÕߣºÕÔÁÖ³¬